Re: To Any Expert with knowledge of Clinical Trial Analysis
Good points; I agree that the OS results from F1 in this subgroup are by far the most promising data out of the publically released topline data. I would want to see some evidence that this OS signal is directly related to the characteristics of MS: perhaps it is related to the much lower toxicity of MS compared to chemo, and we'll probably see if this affected the duration patients were able to sustain therapy shortly. I believe that Anna B. hinted that they will have an updated OS readout for ESMO, and hopefully the OS signal is maintained.
